Aimmune Therapeutics Inc AIMT:NASDAQ

Last Price$27.40NASDAQ Previous Close - Last Trade as of 4:15PM ET 11/19/19

Today's Change+0.45(1.67%)
Bid (Size)$27.00 (10)
Ask (Size)$27.40 (1)
Day Low / High$27.00 - 27.70
Volume876.9 K
  • Latest Stories
  • Commentary and Analysis
Aimmune Says Peanut Allergy Treatment Shows Efficacy
10:48AM ET 11/08/2019 MT Newswires

Aimmune Therapeutics (AIMT) said Friday that new analysis showed consistent efficacy and safety of AR101 across two phase 3 trials in the treatment of...

Aimmune Therapeutics' Peanut Allergy Treatment Talked up at Piper Jaffray, Raymond James
9:00AM ET 10/03/2019 MT Newswires

Shares of Aimmune Therapeutics (AIMT) jumped more than 11% intraday after Piper Jaffray analyst Christopher Raymond forecast a "massive upside" for the...

--Analyst Actions: Cantor Fitzgerald Raises Price Target For Aimmune Therapeutics to $55 From $45, Maintains Overweight Rating
11:56AM ET 9/16/2019 MT Newswires

Price: 23.42, Change: -1.25, Percent Change: -5.07 ...

--Analyst Actions: Stifel Nicolaus Raises Aimmune Therapeutics Price Target to $30 From $24, Maintains Hold Rating
11:55AM ET 9/16/2019 MT Newswires

Price: 23.41, Change: -1.26, Percent Change: -5.11 ...

Sector Update: Health Care Giants Mixed Pre-Bell Monday
9:18AM ET 9/16/2019 MT Newswires

Top Health Care Stocks: JNJ: -0.21% PFE: -0.41% ABT: Flat MRK: +0.06% AMGN: Flat Health care giants were mixed in Monday's pre-market trading. Stocks...

Aimmune Says FDA Committee Votes to Support Approval of Palforzia for Peanut Allergy
3:44AM ET 9/16/2019 MT Newswires

Aimmune Therapeutics (AIMT), a biopharmaceutical company, said late Friday that a special committee convened by the US Food and Drug Administration has...

Aimmune Says FDA to Consider Approval of Peanut Allergy Drug
7:47AM ET 9/13/2019 MT Newswires

Aimmune Therapeutics (AIMT) said a committee of the US Food and Drug Administration is prepared to consider approval of the company's peanut allergy drug...

Aimmune Therapeutics Begins Mid-Stage Trial of Egg Allergy Therapeutic
7:49AM ET 8/21/2019 MT Newswires

Aimmune Therapeutics (AIMT) said pre-market Wednesday that it has randomized its first patient in a phase 2 clinical trial of its investigational...

--Analyst Actions: RBC Cuts PT on Aimmune Therapeutics to $50 From $58; Outperform Speculative Risk Kept
8:46AM ET 8/09/2019 MT Newswires

Price: 19.34, Change: +0.24, Percent Change: +1.26 ...

Sector Update: Health Care Stocks Struggle This Afternoon
4:00PM ET 7/11/2019 MT Newswires

Top Health Care Stocks JNJ -0.96% PFE -2.60% ABT +0.17% MRK -4.42% AMGN -2.29% Health care stocks continued to decline on Thursday, with the NYSE...